Xin Lang Cai Jing·2026-02-02 11:13Group 1 - On January 30, Junshi Biosciences experienced a decline of 2.55% with a transaction volume of 576 million yuan [1] - The financing data for Junshi Biosciences on the same day showed a financing purchase amount of 53.43 million yuan and a net financing purchase of 524.99 thousand yuan, with a total financing and securities balance of 1.479 billion yuan [1] - The financing balance of Junshi Biosciences is at a high level, exceeding the 90th percentile over the past year, accounting for 5.32% of the circulating market value [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and industrialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported an operating income of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [2] - As of September 30, 2025, the number of shareholders of Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]